CO6290712A2 - Asociacion de un inhibidor de corriente sinusual if y de un beta -bloqueante - Google Patents
Asociacion de un inhibidor de corriente sinusual if y de un beta -bloqueanteInfo
- Publication number
- CO6290712A2 CO6290712A2 CO10099973A CO10099973A CO6290712A2 CO 6290712 A2 CO6290712 A2 CO 6290712A2 CO 10099973 A CO10099973 A CO 10099973A CO 10099973 A CO10099973 A CO 10099973A CO 6290712 A2 CO6290712 A2 CO 6290712A2
- Authority
- CO
- Colombia
- Prior art keywords
- association
- blocker
- methyl
- inhibitor
- sinusual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Asociación fija de un inhibidor de corriente sinusal If y de un ß-bloqueante.2.- Asociación según la reivindicación 1, caracterizada porque el inhibidor de corriente sinusal lf es la ivabradina ó 3-{3-[{[(7S)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil}(metil)amino]propil}-7,8-di-metoxi-1,3,4,5-tetrahidro-2H-3-benzazepin-2-ona, o uno de sus hidratos, formas cristalinas o sales de adición a un ácido aceptable farmacéuticamente.3.- Asociación según una de las reivindicaciones 1 ó 2, caracterizada porque el inhibidor de corriente sinusal If es la ivabradina ó 3-{3-[{[(7S)-3,4- dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil} (metil)amino] propil}-7,8-di-metoxi-1,3,4,5-tetrahidro-2H-3-benzazepin-2-ona, hidrocloruro o uno de sus hidratos o formas cristalinas.4.- Asociación según una de las reivindicaciones 1 a 3, caracterizada porque el ß-bloqueante es un ß-bloqueante cardio-selectivo.5.- Asociación según una de las reivindicaciones 1 a 4, caracterizada porque el ß-bloqueante es el atenolol, o uno de sus hidratos, formas cristalinas o sales de adición a un ácido aceptable farmacéuticamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800800A FR2927538B1 (fr) | 2008-02-14 | 2008-02-14 | Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6290712A2 true CO6290712A2 (es) | 2011-06-20 |
Family
ID=39666229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10099973A CO6290712A2 (es) | 2008-02-14 | 2010-08-13 | Asociacion de un inhibidor de corriente sinusual if y de un beta -bloqueante |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8217030B2 (es) |
| EP (2) | EP2409694A1 (es) |
| JP (2) | JP2009191069A (es) |
| KR (1) | KR101078133B1 (es) |
| CN (1) | CN101507726B (es) |
| AP (1) | AP2010005366A0 (es) |
| AR (1) | AR070416A1 (es) |
| AU (1) | AU2009200393B2 (es) |
| BR (1) | BRPI0900470A2 (es) |
| CA (1) | CA2654210C (es) |
| CO (1) | CO6290712A2 (es) |
| CR (1) | CR11628A (es) |
| CU (1) | CU24007B1 (es) |
| CY (1) | CY1114113T1 (es) |
| DK (1) | DK2090303T3 (es) |
| EA (1) | EA200900137A1 (es) |
| EC (1) | ECSP10010402A (es) |
| ES (1) | ES2421893T3 (es) |
| FR (1) | FR2927538B1 (es) |
| GE (1) | GEP20115261B (es) |
| HK (1) | HK1137341A1 (es) |
| HN (1) | HN2010001608A (es) |
| HR (1) | HRP20130617T1 (es) |
| IL (1) | IL207386A0 (es) |
| MA (1) | MA31132B1 (es) |
| ME (1) | ME01014B (es) |
| MX (1) | MX2009001590A (es) |
| MY (1) | MY149122A (es) |
| NI (1) | NI201000139A (es) |
| NZ (1) | NZ574843A (es) |
| PL (1) | PL2090303T3 (es) |
| PT (1) | PT2090303E (es) |
| RS (1) | RS52834B (es) |
| SG (1) | SG155130A1 (es) |
| SI (1) | SI2090303T1 (es) |
| UA (1) | UA99817C2 (es) |
| WO (1) | WO2009115669A1 (es) |
| ZA (1) | ZA200900894B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| US9674435B1 (en) * | 2016-07-06 | 2017-06-06 | Lawrence Maxwell Monari | Virtual reality platforms for capturing content for virtual reality displays |
| KR20190001340A (ko) * | 2017-06-27 | 2019-01-04 | 에리슨제약(주) | 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05503510A (ja) * | 1989-11-21 | 1993-06-10 | セプラカー・インコーポレーテツド | 光学的に純粋な（ｓ）―アテノロールを含む組成物と方法 |
| FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| EP1426051B1 (en) * | 2001-09-11 | 2008-07-16 | Asahi Kasei Pharma Corporation | Medicinal composition for prevention of or treatment for cerebrovascular disorder |
| PT1362590E (pt) | 2002-07-25 | 2004-05-31 | Boehringer Ingelheim Pharma | Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca |
| FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
| CN101095682A (zh) * | 2007-07-23 | 2008-01-02 | 北京本草天源药物研究院 | 一种伊伐布雷定或其药用盐的口服制剂 |
-
2008
- 2008-02-14 FR FR0800800A patent/FR2927538B1/fr active Active
-
2009
- 2009-02-02 SG SG200900692-5A patent/SG155130A1/en unknown
- 2009-02-02 JP JP2009021277A patent/JP2009191069A/ja active Pending
- 2009-02-03 AU AU2009200393A patent/AU2009200393B2/en active Active
- 2009-02-04 EA EA200900137A patent/EA200900137A1/ru unknown
- 2009-02-06 ZA ZA2009/00894A patent/ZA200900894B/en unknown
- 2009-02-06 GE GEAP200911099A patent/GEP20115261B/en unknown
- 2009-02-10 MA MA31623A patent/MA31132B1/fr unknown
- 2009-02-10 UA UAA200901069A patent/UA99817C2/ru unknown
- 2009-02-11 MY MYPI20090515A patent/MY149122A/en unknown
- 2009-02-11 CN CN2009100073196A patent/CN101507726B/zh active Active
- 2009-02-11 US US12/378,080 patent/US8217030B2/en active Active
- 2009-02-12 ME MEP-2010-129A patent/ME01014B/me unknown
- 2009-02-12 CA CA2654210A patent/CA2654210C/fr active Active
- 2009-02-12 NZ NZ574843A patent/NZ574843A/en unknown
- 2009-02-12 WO PCT/FR2009/000156 patent/WO2009115669A1/fr active Application Filing
- 2009-02-12 EP EP11008255A patent/EP2409694A1/fr not_active Withdrawn
- 2009-02-12 AR ARP090100483A patent/AR070416A1/es unknown
- 2009-02-12 MX MX2009001590A patent/MX2009001590A/es active IP Right Grant
- 2009-02-12 SI SI200930649T patent/SI2090303T1/xx unknown
- 2009-02-12 EP EP09290099.2A patent/EP2090303B1/fr not_active Revoked
- 2009-02-12 BR BRPI0900470-0A patent/BRPI0900470A2/pt not_active Application Discontinuation
- 2009-02-12 DK DK09290099.2T patent/DK2090303T3/da active
- 2009-02-12 AP AP2010005366A patent/AP2010005366A0/en unknown
- 2009-02-12 ES ES09290099T patent/ES2421893T3/es active Active
- 2009-02-12 PL PL09290099T patent/PL2090303T3/pl unknown
- 2009-02-12 PT PT92900992T patent/PT2090303E/pt unknown
- 2009-02-12 RS RS20130273A patent/RS52834B/en unknown
- 2009-02-13 KR KR1020090011801A patent/KR101078133B1/ko active IP Right Grant
-
2010
- 2010-01-29 HK HK10101056.7A patent/HK1137341A1/xx unknown
- 2010-08-03 IL IL207386A patent/IL207386A0/en unknown
- 2010-08-10 CU CU2010000162A patent/CU24007B1/es active IP Right Grant
- 2010-08-11 CR CR11628A patent/CR11628A/es unknown
- 2010-08-12 NI NI201000139A patent/NI201000139A/es unknown
- 2010-08-12 EC EC2010010402A patent/ECSP10010402A/es unknown
- 2010-08-13 CO CO10099973A patent/CO6290712A2/es active IP Right Grant
- 2010-08-13 HN HN2010001608A patent/HN2010001608A/es unknown
-
2012
- 2012-07-05 JP JP2012151707A patent/JP2012211179A/ja active Pending
-
2013
- 2013-07-02 HR HRP20130617AT patent/HRP20130617T1/hr unknown
- 2013-07-03 CY CY20131100554T patent/CY1114113T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7691A (es) | Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| EA201201525A1 (ru) | Промышленный способ синтеза солей ивабрадина | |
| ZA201100631B (en) | "production method of isoxazoline-substituted benzoic acid amide compound" | |
| CO6290712A2 (es) | Asociacion de un inhibidor de corriente sinusual if y de un beta -bloqueante | |
| GEP20125491B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| EP2326643A4 (en) | BENZOCHINOL INHIBITOR OF VESICLE MONOAMINE TRANSPORTER 2 | |
| MX2009008443A (es) | Nuevo procedimiento de resolucion de enantiomeros de (3,4-dimetoxi-biciclo[4,2,0]octa-1,3,5-trien-7-il)nitrilo y aplicacion en la sintesis de ivabradina. | |
| GEP20125407B (en) | New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3- benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| CO5790168A1 (es) | Nueva asociacion de un inhibidor de la corriente sinusual if y de un inhibidor de la enzima de conversion y las composiciones farmaceuticas que la contienen | |
| RS54838B1 (sr) | Sprega n-{[(7s)-3,4-dimetoksibiciklo[4.2.0]okta-1,3,5-trien-7-il]metil}-3-(7,8-dimetoksi-1,2,4,5-tetrahidro-3h-3-benzazepin-3-il)-n-metil-3-okso-1-propanamina i perindoprila | |
| AR058575A1 (es) | Asociacion de un inhibidor de la corriente sinusal if y de un inhibidor calcico y las composiciones farmaceuticas que la contienen | |
| MX2012001890A (es) | Sales de lenalidomida. | |
| PE20110098A1 (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| GEP20135970B (en) | New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof | |
| EA200800022A2 (ru) | Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции | |
| CY1116500T1 (el) | Μεθοδος ενζυματικης συνθεσης toy (7s)-1-(3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριεν-7-υλ)-ν-μεθυλομεθαναμινης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων αυτης | |
| CL2011000297A1 (es) | Procedimiento de sintesis de ivabradina utilizando un intermediario de hemitioacetal; y los compuestos intermediarios considerados. | |
| EA200901369A1 (ru) | Применение ивабрадина в качестве диагностического средства в методе коронарной ангиографии путем многослойной компьютерной томографии | |
| MD4468C1 (ro) | Procedeu de sinteză prin lactamizare a ivabradinei şi a sărurilor sale de adiţie cu acizi acceptabili farmaceutic | |
| USD583175S1 (en) | Toothpaste dispenser/toothbrush holder | |
| ITMI20050714A1 (it) | Procedimento di realizzazione di nastri sagomati per etichettature avvolte intorno al relativo prodotto | |
| FR2926184B1 (fr) | Oscillateur piezo-electrique d'allumage de lampe haute tension | |
| TH137164B (th) | การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor)และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน(angiotensin-converting enzyme inhibitor)ในการบำบัดภาวะหัวใจล้มเหลว | |
| TH137164A (th) | การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor) และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน (angiotensin-converting enzyme inhibitor) ในการบำบัดภาวะหัวใจล้มเหลว | |
| TH99437A (th) | สารร่วมสมทบชนิดใหม่ของสารยับยั้งกระแสต่อมไซนัส If และ สารยับยั้งเอนไซม์แปลงเปลี่ยน-แอนไจโอเทนซินและองค์ประกอบในทางเภสัชกรรมที่มีสารนั้น |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |